AI expert intelligence06 Jul 2026
Learn how KnolPersona uses AI to simulate expert perspectives, helping life sciences teams evaluate evidence, identify gaps, and support stronger decisions.
enterprise AI research platform06 Jul 2026
Learn what an enterprise AI research platform is, how it supports life sciences teams, and the key features to evaluate before choosing a solution.
traceable AI pharma06 Jul 2026
Learn what traceable AI is, the standards that support it, and why pharma organizations rely on it for transparent, compliant, and evidence-based decisions.
AI research platform04 Jul 2026
Compare KnolAI and ChatGPT for pharma use cases, including evidence management, traceability, governance, and support for regulated workflows.
enterprise knowledge retrieval04 Jul 2026
Compare KnolAI and Elicit to understand how they support research, evidence management, traceability, and compliance in regulated industries.
enterprise knowledge graph29 Jun 2026
Learn what an enterprise knowledge graph is, how it connects data across life sciences, and why it supports better search, insights, and decision-making.
competitive intelligence29 Jun 2026
Compare competitive intelligence tools for pharma in this 2026 buyer's guide, covering key features, evaluation criteria, and selection considerations.
zero hallucination AI29 Jun 2026
Learn how zero hallucination AI is designed for regulated industries with traceable outputs, governance, and reliable decision support.
AI research platform13 Jun 2026
Examines how AI supports systematic literature reviews through PRISMA-aligned workflows, evidence traceability, and audit-ready documentation.
enterprise intelligence platform13 Jun 2026
Explains how AI helps pharma teams manage evidence and submission requirements across NICE, G-BA, and HAS through coordinated HTA strategies.
private AI platform11 Jun 2026
Explains how sovereign cloud and air-gapped AI deployments help pharma organizations address data security, compliance, and operational requirements.
enterprise knowledge & AI memory platform10 Jun 2026
Explains how agentic AI can support pharma research by working across connected knowledge sources to improve evidence access and decision-making.
enterprise knowledge layer10 Jun 2026
Examines how HEOR teams are adapting evidence strategies for value-based healthcare using AI to support evidence generation and decision-making.
enterprise knowledge graph08 Jun 2026
Compares knowledge graphs and RAG architectures to help enterprise pharma teams evaluate scalability, traceability, and performance needs.
pharma market monitoring08 Jun 2026
Explains how AI supports market access teams with drug pricing intelligence, helping them prepare for evolving pricing pressures and policy changes.
pharma competitive intelligence03 Jun 2026
Reviews the Merck respiratory pipeline, competitive activity, and key market signals shaping strategic decisions and landscape monitoring in 2026.
enterprise intelligence platform01 Jun 2026
Explains how HEOR teams are using AI to support audit-ready value dossiers for ICER, NICE, and G-BA requirements through structured evidence workflows.
life sciences AI platform01 Jun 2026
Explains how AI helps life sciences teams use real-world evidence to address evidence gaps and support stronger HTA submissions for payer review.
pharma competitive intelligence01 Jun 2026
Examines the key pipeline developments, trial activity, and competitive signals shaping how teams are tracking BMS oncology programs in 2026.
clinical competitive intelligence31 May 2026
Explains how life sciences teams can build HTA-ready evidence before Phase III trials and prepare for EU JCA requirements and evidence expectations.
04 May 2026
Explains how clinical trial intelligence is reducing manual landscape analysis in drug development, improving speed, consistency, and planning decisions.
Pharma competitive intelligence04 May 2026
Explains how pharma teams are shifting from quarterly reports to real-time signals for competitive intelligence, improving visibility and faster decision-making.
AI authoring platform04 May 2026
Explains how AI authoring platforms help create living, traceable regulatory submissions in life sciences, supporting consistency, updates, and compliance.
enterprise AI platform29 Apr 2026
An enterprise AI platform enables organizations to build, deploy, and manage AI solutions at scale. Learn how to evaluate trusted, explainable AI systems that meet compliance and transparency requirements in regulated industries.
KnolPersona31 Mar 2026
The EU Joint Clinical Assessment (JCA) regulation became mandatory for these product classes, creating a single EU-level clinical assessment that runs in parallel with the EMA regulatory review, not after it. For pharma teams accustomed to beginning HTA dossier preparation following regulatory approval, this is a strategic and operational discontinuity of the first order.
competitive intelligence29 Mar 2026
In the pharmaceutical industry, where a single competitor's Phase III readout can reshape a multi-billion dollar market overnight, the difference between knowing first and knowing last is not a matter of competitive preference. It is a matter of commercial survival.
AI for drug development27 Mar 2026
For years, AI adoption in drug development has outpaced the regulatory frameworks governing it, leaving sponsors to build AI-powered trial design capabilities on data infrastructure that no agency had formally evaluated.
KnolForge27 Mar 2026
Most pharma organisations in 2026 are not short of AI tools. They have one platform for literature search, another for regulatory writing, a third for competitive monitoring, a standalone modelling tool for health economics, and a generic large language model that teams use informally for drafting and summarisation. Each tool solved a problem at the point of purchase. Together, they have created a new problem: fragmented intelligence, broken audit trails, and compounding governance risk.
KnolAI25 Mar 2026
Consider this scenario: an advisory board meeting is scheduled in three weeks. A payer wants a rapid-turnaround evidence summary on your asset's comparative effectiveness versus the current standard of care. Your HEOR team is still three weeks deep into a manual literature review that will not be complete for another month.
KnolAi23 Mar 2026
Any Transformational change in the pharmaceutical research field often starts with the realisation that the industry’s evidentiary foundation is inherently fragmented.
AI for drug development18 Mar 2026
The structural transformation in clinical trial development began with a tool so routine that its constraints went unquestioned.
AI Software for Healthcare11 Mar 2026
For the better part of a century, the assumption has been this: proprietary data is a competitive advantage, and competitive advantage is never shared.
clinical trial design software04 Mar 2026
Every transformative shift in clinical trial design begins with a question that challenges an assumption so embedded that it is rarely examined. For decades, that assumption has been this: every trial needs a live placebo group.
systematic literature review29 Jan 2026
In the complex landscape of Health Economics and Outcomes Research (HEOR) and Market Access, the systematic literature review is the bedrock of evidence.
KnolScapes27 Jan 2026
In the pharmaceutical industry, the only certainty is uncertainty. Yet, decisions involving billions of dollars and years of development are often made based on linear assumptions that fail to account for the dynamic reality of the market.
AI in healthcare24 Jan 2026
Artificial intelligence is no longer a futuristic concept; it is an operational reality. However, the deployment of AI in life sciences faces a unique hurdle that consumer tech does not: the zero-error mandate. When a recommendation engine suggests the wrong movie, it’s an annoyance.
AI for drug development22 Jan 2026
In the high-stakes world of drug development, timing is everything. Traditionally, teams have treated pharmaceutical competitive intelligence as a monitoring function, something to look at once a study is underway or nearing commercialisation.
AI for drug development21 Jan 2026
The pharmaceutical landscape in 2026 is defined by a paradox: we have more data than ever before, yet the path to a successful approved therapy remains fraught with costly delays.
KnolScape19 Jan 2026
People love to compare drug development to a marathon. It sounds noble, right? The long haul, the endurance, the solitary push.
Knolens SLR16 Jan 2026
In the high-stakes poker game of drug development, playing your hand without watching the other players isn’t bold, it’s reckless.
